Respiratory syncytial virus (RSV) is a significant cause of lower respiratory tract disease in children and individuals with cell-mediated immunodeficiencies. Airway epithelial cells may be infected with RSV, but it is unknown whether other cells within the lung permit viral replication. We studied whether human alveolar macrophages supported RSV replication in vitro. Alveolar macrophages expos...

Cholesterol and sphingolipid enriched lipid raft micro-domains in the plasma membrane play an important role in the life-cycle of numerous enveloped viruses. Although human respiratory syncytial virus (RSV) proteins associate with the raft domains of infected cells and rafts are incorporated in RSV virion particles, the functional role of raft during RSV infection was unknown. In the current st...

Respiratory syncytial virus (RSV) has been around for many years. Symptoms of the includes: cough, runny nose, loss appetite, and a possible ear infection. Often times, patient presents with bronchiolitis, which eventually escalates to RSV. Children most commonly affected by RSV are between ages 0-2. In December 2019, first case SARS-CoV-2 was discovered in China. Normally, sparks winter months...

Abstract Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis only approved treatment modality but costly offered to select vulnerable populations. Here, we investigated gene delivery approaches via recombinant adeno-associated (rAAV2/8) simian immunodeficiency (rSIV.F/HN) vectors achieve sustained vivo production p...

BACKGROUND There is little information that describe the burden of respiratory syncytial virus (RSV) associated disease in the tropical African outpatient setting. METHODS We studied a systematic sample of children aged <5 years presenting to a rural district hospital in Kenya with acute respiratory infection (ARI) between May 2002 and April 2004. We collected clinical data and screened nasal...

Human respiratory syncytial virus (RSV) is a lung tropic virus causing severe airway diseases including bronchiolitis and pneumonia among infants, children, and immuno-compromised individuals. RSV triggers transforming growth factor-β (TGF-β) production from lung epithelial cells and TGF-β facilitates RSV infection of these cells. However, it is still unknown whether RSV infected myeloid cells ...

Human respiratory syncytial virus (RSV) is a major cause of respiratory tract infections worldwide. Several novel small-molecule inhibitors of RSV have been identified, but they are still in preclinical or early clinical evaluation. One such inhibitor is a recently discovered triphenol-based molecule, VP-14637 (ViroPharma). Initial experiments suggested that VP-14637 acted early and might be an...

results among the 158 children evaluated in this study, 49 individuals (31.1%) had rsv infection while nine individuals (5.7%) had hmpv infection. five (55.5%) of the hmpv-infected children were male while four (44.5%) were female and 27 (55.2%) of the rsv-infected patients were females and 22 (44.8%) were males. the rsv infections were detected in mainly < one year old children and hmpv infect...

Respiratory syncytial virus (RSV), the most important cause of lower respiratory disease in infants and young children, is rarely considered among the causes for community-acquired lower respiratory infection in adults. All noninstitutionalized adults hospitalized with community-acquired pneumonia in two Ohio counties were evaluated between December 1990 and May 1992. Fifty-three (4.4%) of 1195...

Therapeutic options to control respiratory syncytial virus (RSV) are limited, thus development of new therapeutics is high priority. Previous studies with a monoclonal antibody (mAb) reactive to an epitope proximal to the central conserved region (CCR) of RSV G protein (mAb 131-2G) showed therapeutic efficacy for reducing pulmonary inflammation RSV infection in BALB/c mice. Here, we show a prot...